Business Overview
Elite Pharmaceuticals is a specialty pharmaceutical company engaged in development and manufacture of oral controlled-release products and generic pharmaceuticals. The company's strategy focuses on manufacturing generic pharmaceutical products with approved ANDAs, developing additional generic products, and expanding through licensing agreements and collaborations. During the period, the company significantly expanded its commercial product portfolio, acquiring multiple ANDAs through a June 2024 asset purchase agreement with Nostrum Laboratories and achieving FDA approvals for several new products including Methotrexate Tablets, Lisdex Capsules, and pain management products (APAP Codeine, APAP Hydrocodone, Oxy APAP, and Methadone).
Key Risk Factors
Key risks include regulatory uncertainty regarding FDA approval timelines and requirements for products under review, as demonstrated by the SequestOx product which remains paused due to prohibitive bioequivalence study costs and uncertain commercial viability. The company faces manufacturing and supply chain dependencies, operating from a single cGMP-certified DEA-registered facility in Northvale, NJ. Additionally, the company is exposed to generic drug market competition and pricing pressures, as well as the termination of the Precision Dose License Agreement on September 10, 2025, which previously provided exclusive distribution rights for multiple products. The company also recognized an impairment charge for Loxapine Capsules due to reassessed future cash flows.
